• About
  • Terms of Use
  • Privacy & Policy
  • Cookie policy
  • “press@ustechtimes.com”.
USTechTimes, Magazine & Review WordPress Theme 2017
  • Home
  • topics
    • All
    • AgTech
    • AI
    • Analytics
    • AR/VR
    • Biotech
    • Blockchain
    • Cars / autonomous vehicles
    • Clean tech / environment
    • Cloud infrastructure
    • Cryptocurrency
    • Data services
    • Developer tools
    • E-commerce
    • Education
    • Energy tech
    • Enterprise
    • Entertainment & sports
    • Security
    PartsTech, a Boston-based car component startup, bags $35 million

    PartsTech, a Boston-based car component startup, bags $35 million

    Gradiant raises $225 million in Series D, enters the unicorn club

    Gradiant raises $225 million in Series D, enters the unicorn club

    Ohmium, a green hydrogen startup closes $250 million Series C

    Ohmium, a green hydrogen startup closes $250 million Series C

    Vedanta Biosciences, a clinical-stage company, secured $106.5 million

    Vedanta Biosciences, a clinical-stage company, secured $106.5 million

    Trending Tags

      • Advertising
      • AgTech
      • AI
      • Analytics
      • AR/VR
      • Biotech
      • Blockchain
      • Cars / autonomous vehicles
      • Clean tech / environment
      • Cloud infrastructure
      • Consumer health & fitness
      • Consumer products
      • Cryptocurrency
      • Data services
      • Developer tools
      • Distributed workforce
      • E-commerce
      • Education
      • Energy tech
      • Enterprise
      • Entertainment & sports
      • Fashion
      • Fintech
      • Food and beverage
      • Games
      • Gaming/eSports
      • Govtech
      • Hardware
      • Health & hospital services
      • Health IT
      • Human capital
      • Impact
      • Insurance
      • IoT
      • Local commerce
      • Lodging/hospitality
      • Logistics
      • Manufacturing
      • Marketing automation
      • Marketplaces
      • Material science
      • Media/content
      • Medical devices
      • Messaging
      • Network infrastructure
      • Parenting/families
      • Payments
      • Pharmaceuticals
      • Real estate/proptech
      • Retail
      • Robotics
      • SaaS
      • Sales and CRM
      • Security
      • SMB software
      • Social commerce
      • Social mobile
      • Space
      • Gaming/eSports
      • Travel
      • Games
    • Interview
    • Venture Capital
    No Result
    View All Result
    • Home
    • topics
      • All
      • AgTech
      • AI
      • Analytics
      • AR/VR
      • Biotech
      • Blockchain
      • Cars / autonomous vehicles
      • Clean tech / environment
      • Cloud infrastructure
      • Cryptocurrency
      • Data services
      • Developer tools
      • E-commerce
      • Education
      • Energy tech
      • Enterprise
      • Entertainment & sports
      • Security
      PartsTech, a Boston-based car component startup, bags $35 million

      PartsTech, a Boston-based car component startup, bags $35 million

      Gradiant raises $225 million in Series D, enters the unicorn club

      Gradiant raises $225 million in Series D, enters the unicorn club

      Ohmium, a green hydrogen startup closes $250 million Series C

      Ohmium, a green hydrogen startup closes $250 million Series C

      Vedanta Biosciences, a clinical-stage company, secured $106.5 million

      Vedanta Biosciences, a clinical-stage company, secured $106.5 million

      Trending Tags

        • Advertising
        • AgTech
        • AI
        • Analytics
        • AR/VR
        • Biotech
        • Blockchain
        • Cars / autonomous vehicles
        • Clean tech / environment
        • Cloud infrastructure
        • Consumer health & fitness
        • Consumer products
        • Cryptocurrency
        • Data services
        • Developer tools
        • Distributed workforce
        • E-commerce
        • Education
        • Energy tech
        • Enterprise
        • Entertainment & sports
        • Fashion
        • Fintech
        • Food and beverage
        • Games
        • Gaming/eSports
        • Govtech
        • Hardware
        • Health & hospital services
        • Health IT
        • Human capital
        • Impact
        • Insurance
        • IoT
        • Local commerce
        • Lodging/hospitality
        • Logistics
        • Manufacturing
        • Marketing automation
        • Marketplaces
        • Material science
        • Media/content
        • Medical devices
        • Messaging
        • Network infrastructure
        • Parenting/families
        • Payments
        • Pharmaceuticals
        • Real estate/proptech
        • Retail
        • Robotics
        • SaaS
        • Sales and CRM
        • Security
        • SMB software
        • Social commerce
        • Social mobile
        • Space
        • Gaming/eSports
        • Travel
        • Games
      • Interview
      • Venture Capital
      No Result
      View All Result
      USTechTimes - Leading Startup and Technology News in the United States
      No Result
      View All Result
      Home Health

      Private pharmaceutical startup Cerevance adds $51 million to its Series B

      Cerevance will use the additional money to support planned clinical trials focusing on schizophrenia, ALS, and Parkinson’s disease.

      USTechTimes Editor by USTechTimes Editor
      February 16, 2023
      Private pharmaceutical startup Cerevance adds $51 million to its Series B
      Share on FacebookShare on Twitter

      Cerevance, a Boston, MA-based drug discovery and development startup working to come up with novel therapeutics drug to treat the disease of the central nervous system (CNS), raised $51 million as an expansion of its Series B funding round.

      Several investors supported the most recent expansion round, including Gates Frontier, Dementia Discovery Fund, Foresite Capital, GV (Google Ventures), Lightstone Ventures, Takeda Ventures, UPMC Enterprises, and Dolby Family Ventures.

      The private clinical stage drug-making company uses its nuclear Enriched Transcript Sort sequencing (NETSseq) tool to treat CNS illnesses. The most recent injection raises the Series B financing’s overall amount to $116 million.

      “We are thrilled to secure additional funding from world-class investors who strongly support the need for novel therapies to treat neurological diseases,” said Craig Thompson, chief executive officer of Cerevance.

      According to a press release from the firm, the additional money will support planned clinical trials focusing on schizophrenia, ALS, and Parkinson’s disease.

      “We are well positioned to continue to advance our clinical and preclinical programs and proprietary NETSseq platform. With this financing, we expect to reach several key clinical milestones across multiple disease areas with unmet needs,” added Craig Thompson.

      Cerevance is developing targeted treatments for patients with neurodegenerative diseases

      Private pharmaceutical business Cerevance focuses on CNS illnesses. The primary drug of Cerevance, CVN424, is an oral, non-dopaminergic molecule that acts on a unique target (GPR6). In Phase 2 research involving 135 Parkinson’s disease patients, the compound showed considerable and clinically significant efficacy.

      The business finds highly selectively expressed, novel target proteins that are either specific to particular brain circuits or are over- or under-expressed in sick brains using its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform.

      Cerevance is developing a strong pipeline of targeted treatments for patients with neurodegenerative diseases, such as Parkinson’s disease, Amyotrophic Lateral Sclerosis, and Alzheimer’s. This pipeline is being advanced through partnerships with over 25 brain banks and the evaluation of an expanding gathering of more than 12,000 human post-mortem brain tissue samples.

      Using its patented NETSseq technology, the startup is now developing various clinical and preclinical initiatives to identify and evaluate novel treatment targets in some of the most challenging neurological illnesses.

      Moreover, Cerevance and Merck, also known as MSD outside of the US and Canada, have a multi-year strategic research partnership to find new Alzheimer’s disease targets using the NETSseq platform.

      As part of the partnership, Cerevance out-licensed one program to Merck in the discovery stage. Also, Cerevance and Takeda are collaborating on research to find new target proteins expressed in the CNS and create new treatments for specific Gastrointestinal illnesses.

      Related Posts

      • New York-based AI firm Dataiku secures $200 million in its Series F

        New York-based AI firm Dataiku secures $200 million in its Series F New York-based artificial…

      • MasterControl secures their first-ever funding of $150 million in its Series A

        MasterControl, a Utah-based quality and manufacturing software solutions provider, has secured its first-ever funding of…

      • Semiconductor design startup Astera Labs bags $150 million in its series D

        Santa Clara, California-based semiconductor design startup Astera Labs galloped into the unicorn club after securing…

      Tags: Clinical TrialHealthHealthtechPharmacy
      USTechTimes Editor

      USTechTimes Editor

      USTechTimes.com is an independent new media site that focuses on the latest technology and digital news in the United States and around the world. The site focuses on new startup launching, startup funding, and development in the startup space.

      Related Posts

      Carrum Health Raises $45M in Series B to Transform Healthcare Delivery
      Health

      Carrum Health Raises $45M in Series B to Transform Healthcare Delivery

      May 31, 2023
      Noah Medical Secures $150 million to build lung scanning robots
      Health

      Noah Medical Secures $150 million to build lung scanning robots

      April 20, 2023
      Pearl Health bags $55 million in a Series B funding round
      Health

      Pearl Health bags $55 million in a Series B funding round

      January 27, 2023
      Aspen Neuroscience sign $40 million debt deal with Silicon Valley Bank
      Biotech

      Aspen Neuroscience sign $40 million debt deal with Silicon Valley Bank

      December 30, 2022
      Wellness technology startup Therabody raises $165 million in growth equity funding
      Health

      Wellness technology startup Therabody raises $165 million in growth equity funding

      September 26, 2022
      New York-based Alma bags $130 million to scale platform for mental healthcare providers
      Health

      New York-based Alma bags $130 million to scale platform for mental healthcare providers

      August 31, 2022
      No Result
      View All Result

      FREE NEWSLETTER

       

      PRODUCTS

      USTechTimes – Leading Startup and Technology News in the United States

      USTechTimes.com is an independent new media site that focuses on the latest technology and digital news in the United States and around the world. The site focuses on new startup launching, startup funding, and development in the startup space.

      More from our network


      • ktd

      • atd

      • itd

      • ktt

      • kgd

      • kpp

      • ktp

      • kpoppost

      • ustechtimes

      Categories

      • Accelerator
      • Animation
      • Apple
      • Applications
      • Artificial Intelligence
      • Advertising
      • AgTech
      • AI
      • Analytics
      • AR/VR
      • About
      • Terms of Use
      • Privacy & Policy
      • Cookie policy
      • “press@ustechtimes.com”.

      © 2023 ustechtimes.com

      No Result
      View All Result
      • Home
      • topics
        • Advertising
        • AgTech
        • AI
        • Analytics
        • AR/VR
        • Biotech
        • Blockchain
        • Cars / autonomous vehicles
        • Clean tech / environment
        • Cloud infrastructure
        • Consumer health & fitness
        • Consumer products
        • Cryptocurrency
        • Data services
        • Developer tools
        • Distributed workforce
        • E-commerce
        • Education
        • Energy tech
        • Enterprise
        • Entertainment & sports
        • Fashion
        • Fintech
        • Food and beverage
        • Games
        • Gaming/eSports
        • Govtech
        • Hardware
        • Health & hospital services
        • Health IT
        • Human capital
        • Impact
        • Insurance
        • IoT
        • Local commerce
        • Lodging/hospitality
        • Logistics
        • Manufacturing
        • Marketing automation
        • Marketplaces
        • Material science
        • Media/content
        • Medical devices
        • Messaging
        • Network infrastructure
        • Parenting/families
        • Payments
        • Pharmaceuticals
        • Real estate/proptech
        • Retail
        • Robotics
        • SaaS
        • Sales and CRM
        • Security
        • SMB software
        • Social commerce
        • Social mobile
        • Space
        • Gaming/eSports
        • Travel
        • Games
      • Interview
      • Venture Capital

      © 2023 ustechtimes.com